文献速递淋巴瘤白血病

纳米罗米地辛:组蛋白去乙酰化酶抑制剂聚合物纳米颗粒在T细胞淋巴瘤模型中改善安全性与疗效

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.
PubMed 文献 · Blood · 2025-01-01

研究开发了基于两亲性二嵌段共聚物纳米化学平台的罗米地辛聚合物纳米颗粒(纳米罗米地辛),在T细胞淋巴瘤小鼠模型中显示出优于罗米地辛的药理特性、耐受性、安全性及抗肿瘤疗效,并在多个模型中验证,包括体外TCL细胞系、大颗粒淋巴细胞白血病患者离体样本及小鼠TCL异种移植瘤。

要点

  • 纳米罗米地辛在T细胞淋巴瘤小鼠模型中耐受性和安全性优于罗米地辛。
  • 纳米罗米地辛在体外TCL细胞系、LGL白血病患者离体样本及小鼠TCL异种移植瘤中显示更优抗肿瘤疗效。
  • 小鼠异种移植模型中纳米罗米地辛肿瘤蓄积更高,总生存期较罗米地辛有统计学显著改善。

核心结论

  • 纳米罗米地辛在T细胞淋巴瘤模型中表现出优于罗米地辛的药理特性、耐受性、安全性及抗肿瘤疗效,这些发现支持在T细胞恶性肿瘤患者中开展纳米罗米地辛的临床开发。

研究设计与样本

  • 研究利用基于两亲性二嵌段共聚物的纳米化学平台开发了罗米地辛的聚合物纳米颗粒(纳米罗米地辛),并在小鼠T细胞淋巴瘤模型、体外TCL细胞系、大颗粒淋巴细胞白血病患者离体样本及小鼠TCL异种移植瘤中进行评价。

主要发现

  • 纳米罗米地辛在T细胞淋巴瘤小鼠模型中表现出更优的药理特性、耐受性和安全性。
  • 纳米罗米地辛在体外TCL细胞系、大颗粒淋巴细胞白血病患者离体样本及小鼠TCL异种移植瘤等多个模型中表现出更优的抗肿瘤疗效。
  • 在小鼠异种移植模型中,纳米罗米地辛较罗米地辛表现出更高的肿瘤蓄积,并达到总生存期的统计学显著改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Histone deacetylase inhibitors (HDACis) are valued treatment options for patients with T-cell malignancies. Romidepsin is a selective class I HDACi initially approved for patients with relapsed or refractory cutaneous and peripheral T-cell lymphomas (PTCLs). Romidepsin was withdrawn from its PTCL indication following a negative randomized phase 4 study (romidepsin-CHOP [cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone]) that showed no benefit over CHOP alone, further diminishing options for patients. Herein, we describe the development of, to our knowledge, a first-in-class polymer nanoparticle (PNP) of romidepsin using an innovative amphiphilic diblock copolymer-based nanochemistry platform. Nanoromidepsin exhibited superior pharmacologic properties with improved tolerability and safety in murine models of T-cell lymphoma (TCL). The PNP also exhibited superior antitumor efficacy in multiple models, including in vitro TCL cell lines, ex vivo samples from patients with large granular lymphocyte (LGL) leukemia, and murine TCL xenografts. Nanoromidepsin demonstrated greater accumulation in tumors and a statistically significant improvement in overall survival compared with romidepsin in murine xenograft models. These findings justify the clinical development of nanoromidepsin in patients with T-cell malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pal I, Illendula A, Joyner A, et al. Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma. Blood. 2025. PMID: 40896830. doi:10.1182/blood.2024027997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。